Scripps Research scientists discover that some membrane-less compartments are built from tiny filaments—a finding that could shape drug development.

Flagging claims about cancer treatment on social media as potentially false might help reduce spreading of misinformation, per online experiment with 1,051 US adults

When removing cancerous tissue in the brain, neurosurgeons often use “awake brain mapping” to minimize the risk of causing unintended disruptions to a patient’s quality of life while removing as much tumor as possible. This practice, which has been used for decades, involves waking a patient up mid-surgery to test their neurocognitive functions in real time by stimulating the brain surface and assessing for functional changes. Now, a study published in the journal Science Advances details a promising, new avenue toward improving awake brain mapping results by investigating the tiny, nearly imperceptible variabilities in patient behavior that occur during the procedure. This work points to a future where brain surgeries are not just safer, but more precisely tailored to protect each patient’s speech, movement and quality of life.

What if cancer drugs could stay dormant until they reach cancer cells? A new study by Syracuse University researchers demonstrates a promising chemistry-based strategy that could do just that.

5-methylcytosine RNA modification is a key regulator of neuroblastoma oncogenesis and differentiation. NSUN6, a 5-methylcytosine-specific messenger RNA methyltransferase, modulates messenger RNA methyltransferase activity and translation termination. Yet, its potential link to neuroblastoma risk has not been previously reported. The present study aimed to reveal the relationship between NSUN6 gene polymorphisms and the risk of neuroblastoma in children from Jiangsu province.

BUFFALO, NY – February 25, 2026 – A new editorial perspective was published in Volume 17 of Oncotarget on February 20, 2026, titled “CAR-T therapy: Trailblazing CAR(ing) in cancer treatment.”

An international consortium of 48 researchers from institutions in France, Sweden, and the United States has won the 2025 edition of the Bial Award in Biomedicine, a €350,000 prize promoted by the Bial Foundation to recognise a published work of exceptional quality and scientific relevance in the field of biomedicine.

Accumulating evidence indicates that fecal syndecan-2 (SDC2) methylation is a promising biomarker for early detection of colorectal cancer. This study aimed to investigate the diagnostic efficacy of fecal SDC2 methylation testing for adenomas and evaluate the risk stratification efficacy of the Asia-Pacific Colorectal Screening Scoring (APCS) combined with SDC2 methylation status.